UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035710
Receipt number R000040628
Scientific Title A Study on the Effect of Food Containing Plant Extract on Postprandial Blood Glucose -A Randomized, Double-blind, Placebo-controlled, Cross-over Study-
Date of disclosure of the study information 2019/02/01
Last modified on 2021/02/17 10:43:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study on the Effect of Food Containing Plant Extract on Postprandial Blood Glucose
-A Randomized, Double-blind, Placebo-controlled, Cross-over Study-

Acronym

A Study on the Effect of Food Containing Plant Extract on Postprandial Blood Glucose

Scientific Title

A Study on the Effect of Food Containing Plant Extract on Postprandial Blood Glucose
-A Randomized, Double-blind, Placebo-controlled, Cross-over Study-

Scientific Title:Acronym

A Study on the Effect of Food Containing Plant Extract on Postprandial Blood Glucose

Region

Japan


Condition

Condition

No

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To comfirm the effect of food containing plant extract on postprandial blood glucose

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood glucose AUC

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Food containing plant extract, single ingestion. Wash out. Food not containing plant extract, single ingestion.

Interventions/Control_2

Food not containing plant extract, single ingestion. Wash out. Food containing plant extract, single ingestion.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

(1)Males and females aged 20 to 64 years-old.
(2)Subjects whose fasting blood glucose level is from 100 mg/dL to 125 mg/dL or two-hour blood glucose level after 75 g glucose loading is from 140 mg/dL to 199 mg/dL, and causal blood glucose level is under 200 mg/dL and who are judged normal-high or borderline type as the state of glycemia by the principal investigator.
(3) Subjects who do not habitually consume a large amounts of alcohol.
(4)Subjects who can make self-judgment and are voluntarily giving written informed consent.

Key exclusion criteria

(1) Subjects whose fasting blood glucose level is 126 mg/dL and over or two-hour blood glucose level after 75 g glucose loading is 200 mg/dL and over.
(2) Subjects who use medications affecting blood glucose level.
(3) Subjects who can't stop using supplements and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) affecting blood glucose level during test periods.
(4) Subjects who have declared allergic reaction to ingredients contained in test foods or loading foods.
(5) Subjects who are diagnosed as diabetes by the screening tests I or II.
(6) Subjects who contract, are under treatment for or have a history of serious diseases (e.g., kidney and liver disease, and heart disease), thyroid gland disease, adrenal gland disease, and/or metabolic disorder.
(7) Subjects who have a chronic disease and regularly use medications.
(8) Subjects who have a history and/or a surgical history of digestive disease affecting digestion and absorption.
(9) Subjects who are judged unsuitable for the current study by the screening tests.
(10) Subjects who are diagnosed as anemic by the screening tests and unsuitable for frequent blood sampling.
(11) Subjects who have had diarrhea within the last one week prior to the screening tests.
(12) Subjects who have donated over 200 mL of blood and/or blood components within the last one month or over 400 mL of blood and/or blood components within the last three months prior to the current study.
(13) Subjects who are under treatment for or have a history of drug addiction and/or alcoholism.
(14) Subjects who are planning to participate in other clinical studies during test periods and/or had participated in other clinical studies within the last one month prior to the current study.
(15) Subjects who are planning to become pregnant after informed consent, pregnant or lactating.
(16) Subjects who are judged unsuitable for the current study by the investigator for other reasons.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Yoshitaka
Middle name
Last name Iwama

Organization

Nihonbashi Cardiology Clinic

Division name

Director

Zip code

103-0001

Address

Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo

TEL

03-5641-4133

Email

yiwama@well-sleep.jp


Public contact

Name of contact person

1st name Yoshika
Middle name
Last name Komori

Organization

KSO Corporation

Division name

Sales department

Zip code

105-0023

Address

1-9-7 Shibaura, Minato-ku, Tokyo

TEL

03-3452-7733

Homepage URL


Email

yoshi@kso.co.jp


Sponsor or person

Institute

KSO Corporation

Institute

Department

Personal name



Funding Source

Organization

TOYO SHINYAKU Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Nihonbashi Cardiology Clinic

Address

Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo

Tel

03-5641-4133

Email

niho-jimucho@well-sleep.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 02 Month 01 Day


Related information

URL releasing protocol

https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000040628

Publication of results

Published


Result

URL related to results and publications

http://www.pieronline.jp/content/article/0386-3603/47080/1245

Number of participants that the trial has enrolled

50

Results

Statistically significant difference was confirmed in the primary outcome.

Results date posted

2020 Year 04 Month 17 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Males and females aged 20 to 64 years old.

Participant flow

Enrolled(n=50)
Completed(n=49)
Analysed(n=46)

Adverse events

No adverse events were observed that be related to test food.

Outcome measures

Blood glucose AUC

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2018 Year 12 Month 25 Day

Date of IRB

2019 Year 01 Month 11 Day

Anticipated trial start date

2019 Year 02 Month 02 Day

Last follow-up date

2019 Year 04 Month 18 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 01 Month 29 Day

Last modified on

2021 Year 02 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040628


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name